CASBF - Week In Review: BeiGene Signs $540 Million Deal For China Rights To 3 HBV Candidates
Deals and Financing
Beijing's BeiGene (NSDQ: [[BGNE]]; HK: 06160) in-licensed Greater China rights to three inhibitors for chronic hepatitis B virus ((HBV)) from Assembly Biosciences (NSDQ: [[ASMB]]) in a $540 million agreement. All three molecules have started US clinical trials. BeiGene, which will make a $40 million upfront payment, is responsible for $500 million in milestones, plus royalties. BeiGene will contribute initial funding for China clinical development; subsequent costs will be shared equally.
Shanghai HaiHe Biopharma completed a $171 million Series C round led by Warburg Picus to advance its portfolio of innovative drugs. The